Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas
Clinical trial NCT04122911 · COMPLETED
Trial details
- NCT number
- NCT04122911
- Sponsor
- National Cancer Institute, Naples
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-01-29
- Primary completion
- 2017-12-30
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.